MX2021010058A - Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. - Google Patents

Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.

Info

Publication number
MX2021010058A
MX2021010058A MX2021010058A MX2021010058A MX2021010058A MX 2021010058 A MX2021010058 A MX 2021010058A MX 2021010058 A MX2021010058 A MX 2021010058A MX 2021010058 A MX2021010058 A MX 2021010058A MX 2021010058 A MX2021010058 A MX 2021010058A
Authority
MX
Mexico
Prior art keywords
skin disorders
treating facial
rapamycin formulations
topical rapamycin
facial angiofibromas
Prior art date
Application number
MX2021010058A
Other languages
English (en)
Inventor
Paul Beckett
Henri Lichenstein
Tian Xu
Jonathan M Rothberg
Jeff Grotzke
Keith Fandrick
Original Assignee
Ai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Therapeutics Inc filed Critical Ai Therapeutics Inc
Publication of MX2021010058A publication Critical patent/MX2021010058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona composiciones de gel de rapamicina para administración tópica y composiciones y métodos relacionados que incluyen su uso en el tratamiento de una afección, enfermedad o trastorno de la piel.
MX2021010058A 2019-02-20 2020-02-19 Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. MX2021010058A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962807786P 2019-02-20 2019-02-20
US201962835630P 2019-04-18 2019-04-18
PCT/US2020/018816 WO2020172266A1 (en) 2019-02-20 2020-02-19 Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Publications (1)

Publication Number Publication Date
MX2021010058A true MX2021010058A (es) 2021-11-12

Family

ID=70009373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010058A MX2021010058A (es) 2019-02-20 2020-02-19 Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.

Country Status (12)

Country Link
US (1) US20200261427A1 (es)
EP (1) EP3927319A1 (es)
JP (1) JP2022521006A (es)
KR (1) KR20210130769A (es)
CN (1) CN113710232A (es)
AU (1) AU2020226527A1 (es)
BR (1) BR112021016296A2 (es)
CA (1) CA3131232A1 (es)
IL (1) IL285715A (es)
MX (1) MX2021010058A (es)
TW (1) TW202045165A (es)
WO (1) WO2020172266A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003497A2 (pt) * 2018-08-30 2021-05-18 Chemistryrx. composições contendo sirolimo
US20220142990A1 (en) * 2019-02-27 2022-05-12 Osaka University External preparation for treating a vascular anomaly
AU2020411442A1 (en) * 2019-12-26 2022-06-23 Santen Pharmaceutical Co., Ltd. Aqueous suspension composition containing sirolimus or salt thereof
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition
CN113332228B (zh) * 2021-04-29 2023-03-31 杭州中美华东制药有限公司 一种西罗莫司凝胶制剂
JP2024533480A (ja) * 2021-09-15 2024-09-12 パルヴェラ セラピューティクス、インク． ラパマイシン組成物および小嚢胞性リンパ管奇形の治療におけるそれらの使用
WO2024034627A1 (ja) * 2022-08-12 2024-02-15 国立大学法人群馬大学 シロリムスを含む、全身性強皮症における皮膚硬化を治療するための皮膚外用薬
CN116509849A (zh) * 2023-05-26 2023-08-01 首都医科大学附属北京儿童医院 雷帕霉素在制备辅助治疗咖啡斑药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
WO2004014222A2 (en) 2002-08-12 2004-02-19 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008531686A (ja) 2005-03-02 2008-08-14 ワイス ラパマイシンの精製
CA2637255C (en) 2006-02-02 2018-06-12 Novartis Ag 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US20120022095A1 (en) 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
RU2571277C2 (ru) * 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20130102572A1 (en) 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
ES2797376T3 (es) * 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
TWI756168B (zh) * 2015-02-02 2022-03-01 日商參天製藥股份有限公司 多微泡及其眼瞼投予
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy

Also Published As

Publication number Publication date
CA3131232A1 (en) 2020-08-27
IL285715A (en) 2021-10-31
WO2020172266A1 (en) 2020-08-27
JP2022521006A (ja) 2022-04-04
WO2020172266A9 (en) 2020-10-22
EP3927319A1 (en) 2021-12-29
US20200261427A1 (en) 2020-08-20
TW202045165A (zh) 2020-12-16
CN113710232A (zh) 2021-11-26
AU2020226527A1 (en) 2021-10-14
BR112021016296A2 (pt) 2021-11-09
KR20210130769A (ko) 2021-11-01

Similar Documents

Publication Publication Date Title
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
MX2024010140A (es) Nuevos metodos.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
EP3922297A4 (en) DEVICE FOR SKIN CARE, COSMETICS AND MEDICAL TREATMENT
EP3590338A3 (en) Medical treatments based on anamorelin
PH12020551179A1 (en) Methods for treating mitochondrial disorder
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
WO2020039088A3 (en) Aromatic molecules for use in the treatment of pathological conditions
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы